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Abstract
Objective: An emerging theme in modern biology is that
adipose tissue can respond to metabolic stress, and to inflam-
matory stimuli, by regulating the secretion of a complex net-
work of soluble mediators, termed adipokines. Adiponectin,
the most prevalent circulating adipokine in human, has pro-
found insulin-sensitizing and anti-inflammatory properties.
Indeed, the notion that adiponectin plays an important role
in the interactions between the metabolic and the immune
systems has been strongly suggested. Thus, the aim of this
study was to determine if pyelonephritis during pregnancy is
associated with changes in maternal serum adiponectin
concentrations.
Study design: This cross-sectional study included women in
the following groups: 1) normal pregnant women (ns200);
and 2) pregnant women with pyelonephritis (ns50). Mater-
nal plasma adiponectin concentrations were determined by














Results: 1) The median maternal plasma adiponectin con-
centration was lower in patients with pyelonephritis than in
those with a normal pregnancy (P-0.001); 2) among preg-
nant women with a normal weight, patients with pyelone-
phritis had a lower median plasma adiponectin concentration
than those with a normal pregnancy (P-0.001); 3) similarly,
among overweight/obese patients, those with pyelonephritis
had a lower median plasma adiponectin concentration than
those with a normal pregnancy (P-0.001); and 4) the pres-
ence of pyelonephritis was independently associated with
maternal plasma adiponectin concentrations after adjustment
for maternal age, smoking, gestational age at sampling, and
pregestational body mass index (BMI).
Conclusion: 1) The findings that acute pyelonephritis in
pregnancy is characterized by low maternal plasma concen-
trations of adiponectin in both lean and overweight/obese
patients are novel and concur with the antiinflammatory
properties of adiponectin; and 2) the results of this study
support the notion that adiponectin may play a role in the
intricate interface between inflammation and metabolism
during pregnancy.
Keywords: Acute bacterial infection; adipokines; adiponec-
tin; infection; inflammation; pregnancy; pyelonephritis.
Introduction
Adipose tissue has emerged as an active endocrine organ w41,
110x that can orchestrate not only a metabolic response to
insults, but also an inflammatory response. The mechanisms
by which adipose tissue exerts its effects on the immune
system have not been completely elucidated. A growing
body of evidence suggests that adipocytes modulate resident
immune cell functions directly or indirectly, in a paracrine
and/or endocrine fashion via the secretion of adipokines w19,
90x. The latter is a group of active molecules which are adi-
pocytesspecific or enriched proteins, and includes adiponec-
tin w5, 40, 99x, leptin w126x, resistin w35, 45, 97, 108x, visfatin
w38, 101x, and others w105, 110x. Adipokines have been
implicated in a vast array of physiological processes, as well
as in inflammation-related pathological conditions such as
asthma w31, 32x, inflammatory bowel disease w112x, rheu-
matoid arthritis w9, 98x, multiple sclerosis w7x and obesity w5,
22, 24, 46, 58, 68, 70, 77–79, 88, 120x. The metabolic and
inflammatory effects of adipokines have been recently cor-
roborated by reports concerning pregnant women, suggesting
that adipokines play a role in metabolic adaptations to nor-
mal gestation w11, 62, 64, 66, 68, 70, 78, 79, 106x, as well
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as in inflammationrelated w49, 59, 60, 67, 68, 71, 77, 113x
and other complications of pregnancy w61, 63, 65, 69x.
Adiponectin, identified independently by four groups w37,
55, 76, 99x, is the adipokine that circulates in the highest
concentrations in humans. The range of adiponectin’s bio-
logical actions includes insulin-sensitizing w8, 119x, anti-ath-
erogenesis w25, 84x, and angiogenesis w86, 103x. In addition
to its well-established role in glucose metabolism and vas-
culature protection, adiponectin has anti-inflammatory prop-
erties w13, 104x. Furthermore, adiponectin is involved in the
modulation of both the innate and adaptive limbs of the
immune system w82, 83, 96, 117, 118, 123, 124x.
Activation of the innate immune response and suppression
of the adaptive immune response are hallmarks of normal
human pregnancy w95x. Teleologically, these immunologic
alterations aim to promote tolerance to the fetus and protect
the mother against infection w74, 95x. Nevertheless, pregnant
women are more susceptible to infections w15, 50, 91–93x
including those of the lower urinary tract w20, 51x and pye-
lonephritis w27x. Furthermore, pregnant women with an epi-
sode of acute pyelonephritis are at risk of developing sepsis
and adult respiratory distress syndrome (ARDS) w17, 89x,
though both complications are rare in young non-pregnant
individuals. Recently, our group suggested that intraamniotic
adipokines may play a role in the innate immune response
against intra-amniotic infection/inflammation (IAI) w49, 67,
113x. However, despite the compelling evidence supporting
the metabolic and inflammatory effects of adiponectin, no
data exist about the association between circulating maternal
adiponectin and acute systemic bacterial infections. More-
over, the serum/plasma adiponectin concentration in patients
with pyelonephritis has not been reported either in pregnant
or non-pregnant subjects. Thus, the aim of our study was to
determine whether pyelonephritis during pregnancy is asso-
ciated with changes in maternal plasma adiponectin
concentrations.
Materials and methods
Study design and population
A cross-sectional study was conducted by searching our clinical
database and bank of biological samples, and included patients in
the following groups: (1) normal pregnancy (ns200), and (2) preg-
nant women with pyelonephritis (ns50). Women were considered
to have a normal pregnancy if they met the following criteria: (1)
no medical, obstetrical, or surgical complications, (2) absence of
labor at the time of venipuncture, and (3) delivery at term
(G37 weeks) of a normal healthy infant whose birth weight was
between the 10th and 90th percentile for gestational age w29x. Pye-
lonephritis was diagnosed in the presence of fever (temperature
G388C), clinical signs of an upper urinary tract infection (e.g., flank
pain, costovertebral angle tenderness), and a positive urine culture
for microorganisms.
The body mass index (BMI) was calculated according to the for-
mula: weight (kg)/height (m2). Normal weight women were defined
as those with a BMI of 18.5–24.9 kg/m2, according to the definition
of the World Health Organization (WHO) w1x. The study population
was further classified by the pre-gestational BMI into two groups:
normal weight and overweight/obese (BMI G25 kg/m2).
All participating women provided written informed consent prior
to enrolment and the collection of blood samples. The collection
and use of blood for research purposes was approved by the Insti-
tutional Review Boards of both the Sotero del Rio Hospital (Chile)
and the Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD) (Bethesda, Maryland, USA).
Many of these samples have previously been used to study the biol-
ogy of inflammation, hemostasis, and growth factor concentrations
in normal pregnant women and those with pregnancy complications.
Maternal sample collection and determination of
adiponectin concentrations
Maternal blood was collected in vials containing ethylenediamine-
tetra-acetic acid, and centrifuged at 2500 RPM for 10 min at 48C.
The plasma obtained was stored at –808C until analysis. Plasma
adiponectin concentrations were determined with the Human Adi-
ponectin ELISA (LINCO Research Inc, St Charles, MO, USA)
according to the manufacturer’s instructions. The sensitivity of the
assay was 0.91 ng/mL, and the intra- and inter-assay coefficients of
variation were 4.6% and 6.6%, respectively.
Statistical analysis
Normality of the data was tested using the Kolmogorov-Smirnov
tests. Since plasma adiponectin concentrations were not normally
distributed, non-parametric test were used for analysis. Comparisons
between the two groups were performed using the Mann-Whitney
U-test for continuous variables and the x2-test for categorical
variables. Multiple linear regression analysis was used to determine
which factors were significantly and independently associated with
maternal plasma adiponectin concentration. The following parame-
ters were included in the model: maternal age, smoking, gestational
age at sampling, pregestational BMI and the presence of pyelone-
phritis. A P-0.05 was considered statistically significant. Analysis
was performed with SPSS, version 14 (SPSS Inc., Chicago, IL,
USA).
Results
The demographic and clinical characteristics of women with
a normal pregnancy and those with pyelonephritis are dis-
played in Table 1. The median birthweight was significantly
lower in patients with pyelonephritis than in those with a
normal pregnancy. Table 2 displays the maternal demograph-
ic and clinical characteristics of all pregnant women accord-
ing to BMI category (normal weight vs. overweight/obese).
There were no significant differences in age, nulliparity,
smoking status, gestational age at sampling, gestational age
at delivery or birthweight between normal weight and over-
weight/obese women either in the normal pregnancy or pye-
lonephritis groups.
Adiponectin concentrations in pyelonephritis vs.
normal pregnancy
The median maternal plasma adiponectin concentration was
lower in patients with pyelonephritis than in those with a
normal pregnancy (median: 7223 ng/mL, interquartile range
wIQRx 5852–8962 vs. 10,430 ng/mL, IQR 9262–12,112;
P-0.001, Figure 1).
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Table 2 Clinical and demographic characteristics of the study population according to body mass index.
Normal pregnancy P-value Pyelonephritis P-value
Normal weight Overweight/obese Normal weight Overweight/obese
(ns149) (ns51) (ns35) (ns15)
Maternal age 25 27 0.2 24 28 0.7
(years) (20–31) (22–31) (21–31) (21–29)
Nulliparity 62 (42%) 16 (31%) 0.2 17 (48%) 6 (40%) 0.8
Smoking 12 (8%) 2 (4%) 0.4 5 (14%) 2 (13%) 0.9
Pre-gestational BMI 22.3 26.9 -0.001 21.6 27.4 0.02
(kg/m2) (20.8–23.4) (26.0–30.0) (19.9–23.1) (26.0–28.4)
BMI at blood sampling 25.8 31.5 -0.001 24.7 28.0 0.02
(kg/m2) (24.0–27.7) (29.3–34.0) (22.3–25.6) (27.4–31.0)
GA at blood sampling 29.1 29.2 0.4 28.8 28.2 0.3
(weeks) (24.7–33.7) (25.8–38.4) (21.4–34.4) (21.5–32.1)
GA at delivery 40.0 39.7 0.8 39.1 40.0 0.9
(weeks) (38.6–40.0) (39.0–40.4) (38.3–39.1) (37.3–40.3)
Birth weight (g) 3410 3440 0.5 3140 3160 0.3
(3210–3780) (3155–3670) (3020–3430) (2640–3780)
Values are expressed as median (interquartile range) or numbers (%); GAsgestational age, BMIsbody mass index.
Table 1 Clinical and demographic characteristics of the study population.
Normal pregnancy Pyelonephritis P-value
(ns200) (ns50)
Maternal age (years) 26 (21–31) 27 (21–30) 0.9
Nulliparity 78 (36%) 23 (46%) 0.4
Smoking 14 (7%) 7 (14%) 0.1
Pre-gestational BMI (kg/m2) 23.1 (21.1–24.9) 22.7 (20.2–25.6) 0.5
BMI at blood sampling (kg/m2) 26.9 (24.8–29.6) 25.4 (23.7–27.9) 0.09
GA at blood sampling (weeks) 31.0 (25.3–38.2) 28.9 (21.6–33.2) 0.2
GA at delivery (weeks) 39.8 (38.6–40.3) 39.2 (38.2–40.1) 0.09
Birth weight (g) 3400 (3172–3670) 3140 (2990–3505) -0.01
Values are expressed as median (interquartile range) or numbers (%); GAsgestational age, BMIsbody mass index.
Adiponectin concentrations in pyelonephritis: normal
weight vs. overweight/obesity
Among patients with pyelonephritis, the median maternal
plasma adiponectin concentration was lower in overweight/
obese patients than in those with a normal weight (5164
ng/mL, IQR 4805–7997 vs. 7467 ng/mL, IQR 6649–9213;
Ps0.02).
Adiponectin concentrations in normal weight
pregnant women: pyelonephritis vs. normal
pregnancy
Among pregnant women with a normal weight, those with
pyelonephritis had a lower median plasma adiponectin con-
centration than women with a normal pregnancy (7467
ng/mL, IQR 6649–9213 vs. 10,610 ng/mL, IQR
9351–12,255; P-0.001, Figure 2).
Adiponectin concentrations in overweight/obese
pregnant women: pyelonephritis vs. normal
pregnancy
Among overweight/obese pregnant women, those with pye-
lonephritis had a lower median plasma adiponectin concen-
tration than women with a normal pregnancy (5164 ng/mL,
IQR 4805–7997 vs. 9981 ng/mL, IQR 8801–11,850;
P-0.001, Figure 3).
Multiple linear regression analysis was employed to exam-
ine the relationship between the plasma concentrations of
adiponectin and pyelonephritis, while adjusting for maternal
age, smoking status, and gestational age at blood sampling.
The final regression model suggested that the presence of
pyelonephritis and pre-gestational BMI were independently
associated with low maternal plasma adiponectin concentra-
tions (P-0.001 and Ps0.03, respectively).
Discussion
Principal findings of the study
1) The median maternal plasma adiponectin concentration
was significantly lower in patients with pyelonephritis than
in those with a normal pregnancy; 2) among pregnant women
with a normal weight, those with pyelonephritis had a sig-
nificantly lower median plasma adiponectin concentration
than women with a normal pregnancy; 3) similarly, among
pregnant women with overweight/obesity, those with pyelo-
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Figure 1 Comparison of the median maternal plasma adiponectin
concentration between women with normal pregnancies and patients
with pyelonephritis.
The median maternal plasma adiponectin concentration was lower
in patients with pyelonephritis than in those with a normal preg-
nancy (7223 ng/mL, IQR 5852–8962 vs. 10,430 ng/mL, IQR
9262–12,112; P-0.001).
Figure 2 Comparison of the median maternal plasma adiponectin
concentration in normal weight pregnant women with normal preg-
nancy and patients with pyelonephritis.
Among pregnant women with a normal weight, those with pyelo-
nephritis had a lower median plasma adiponectin concentration than
women with a normal pregnancy (7467 ng/mL, IQR 6649–9213 vs.
10,610 ng/mL, IQR 9351–12,255; P-0.001).
Figure 3 Comparison of the median maternal plasma adiponectin
concentration in overweight/obese pregnant women with normal
pregnancy and patients with pyelonephritis.
Among overweight/obese pregnant women, those with pyelone-
phritis had a lower median plasma adiponectin concentration than
women with a normal pregnancy (5164 ng/mL, IQR 4805–7997 vs.
9981 ng/mL, IQR 8801–11,850; P-0.001).
nephritis had a significantly lower median plasma adiponec-
tin concentration than women with a normal pregnancy; and
4) the presence of pyelonephritis was independently associ-
ated with maternal plasma adiponectin concentrations after
adjustment for maternal age, smoking, gestational age at
sampling, and pre-gestational BMI.
Pregnancy and pyelonephritis – an ominous
combination
Pyelonephritis complicates 1–2% of pregnancies w34, 72x,
and it is one of the most common indications for antepartum
hospitalization w6, 23x. Pyelonephritis occurs ;70% of the
time during the second and third trimesters, 25% in the post-
partum period and only 4% of cases present during the first
trimester w27, 72x. The clinical course of most patients is
favorable and resolution of the fever is expected in 95% of
the cases within 72 h of adequate antimicrobial treatment
w72x. Nonetheless, pregnant women with pyelonephritis are
at risk of developing sepsis w10, 53, 102x and ARDS w3, 12,
14, 16, 21, 33, 34, 52, 89x. Moreover, pyelonephritis is the
most common cause of septic shock during pregnancy w53,
102x and the most frequent indication for admission to
obstetric intensive care units w125x.
Adiponectin and immunity: bridging the gap
between inflammation and metabolism?
Adiponectin, the most abundant gene (AMP1) product of adi-
pose tissue w37, 55, 76, 99x, has a wide range of biological
activities. Adiponectin has been implicated in the pathophy-
siology of insulin resistance w8, 36, 73, 115, 119x, athero-
sclerosis w81, 83, 85x, hypertension w39, 42x, and
dyslipidemia w18, 57x. In addition to its wellcharacterized
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metabolic effects, several lines of evidence suggest that
adiponectin is an important mediator of inflammatory
responses: 1) adiponectin suppresses macrophage production
of pro-inflammatory cytokines, such as TNF-a w124x, (IFN-
g) w117x and IL-6 w100x; 2) exposure of macrophages to adi-
ponectin results in inhibition of their phagocytic activity in
response to stimulation with lipopolysaccharide (LPS) w124x;
3) adiponectin inhibits activation of the nuclear transcription
factor NF-kB in endothelial cells w85x; and 4) in knockout
mice, gene deletion of adiponectin results in higher TNF-a
mRNA expression in adipose tissue, as well as higher cir-
culating TNF-a concentrations than ‘‘adiponectin-suffi-
cient’’ mice (wild type) w56x. Taken together, this unique
combination of biological effects makes adiponectin a plau-
sible candidate to orchestrate the functional interphase
between metabolism and inflammation.
Pyelonephritis is characterized by low maternal
circulating adiponectin
The findings reported herein characterize pyelonephritis dur-
ing pregnancy as a condition associated with low maternal
circulating adiponectin concentrations. Moreover, lower
maternal concentrations were detected in pyelonephritis in
patients who were either of normal weight or overweight/
obese. These findings are novel. Reports concerning circu-
lating adiponectin concentrations in the presence of
infectious disorders in nonpregnant patients are scarce and
no data exist concerning maternal circulating concentrations
of this adipokine in any infectious disease. Furthermore, no
information regarding plasma/serum adiponectin concentra-
tions in the presence of pyelonephritis either in non-pregnant
or in pregnant patients is available.
The findings reported herein contrast with two studies that
examined the effect of experimental endotoxemia on human
circulating adiponectin concentrations. Keller et al. w43x
reported no change in adiponectin plasma concentrations in
endotoxin-injected subjects (ns23). Similarly, Anderson et
al. w4x found no significant difference in plasma adiponectin
before and after intra-venous endotoxin injection (ns20).
Differences in study design may contribute to explain the
apparent inconsistency between the studies. Specifically, the
studies of Keller et al. w43x and Anderson et al. w4x included
only 4 and 10 women, respectively, and pregnancy was an
exclusion criterion. In addition, the study population was
younger than the one included in the present study, and
almost all participants had a normal BMI. Finally, the effect
on adiponectin concentrations was determined in both studies
no more than 24 h after exposure to the endotoxin.
Why is pyelonephritis associated with low maternal
adiponectin concentrations?
Several possibilities can account for the low maternal cir-
culating adiponectin concentrations and pyelonephritis:
1. Regulatory mechanism to increase insulin resistance – An
episode of acute infection imposes metabolic challenges
to the mother. Indeed, acute infection/inflammation is
associated with hypermetabolism, enhanced energy
expenditure, and insulin resistance w26, 28, 109, 111x.
The acute nature of pyelonephritis necessitates prompt
metabolic adaptations to ensure constant flow of nutrients
to both the fetus and the mother. The low maternal plas-
ma adiponectin concentrations reported herein in patients
with pyelonephritis favor a state of insulin resistance
which enhances the availability of glucose to the fetus.
Thus, it is conceivable that the low concentrations of cir-
culating adiponectin are part of the metabolic adaptations
aimed at ensuring the flux of glucose to the fetus.
2. Counter-inflammatory response – Low concentrations of
circulating adiponectin have been associated with the
presence of systemic inflammation. Indeed, patients with
inflammatory bowel disease w114x, atopic dermatitis and
eczema w75x, asthma and overweight/obesity w2, 5, 37, 44,
78, 88x have lower circulating adiponectin concentrations
than normal controls. The results of the present study
support the association between pro-inflammatory con-
ditions and low adiponectin concentrations and extend
these data by showing that low circulating concentrations
of this adipokine characterize acute bacterial infection
during pregnancy.
3. Binding to circulating lipopolysaccharide (LPS) – Bac-
teremia is a common finding in pregnant women with
pyelonephritis since 15–45% of patients have a positive
blood culture w30, 48, 54, 80, 107x. Furthermore, pyelo-
nephritis-related sepsis is the most frequent indication for
admission to obstetric intensive care units w125x, as well
as the most common cause of septic shock during preg-
nancy w53, 102x. Bacterial pathogens that are isolated
from blood cultures rarely differ from those that are found
in the corresponding urine culture and include predomi-
nantly Gram-negative bacteria that possess endotoxin
(e.g., E. coli and Klebsiella pneumoniae). A recent report
demonstrated that human adiponectin directly binds LPS
derived from several different bacteria including E. coli
w87x. It was proposed that adiponectin infiltrates into
inflammation sites, and may act as a scavenging anti-
inflammatory agent through its interaction with LPS w87x.
It is tempting to suggest that the low circulating maternal
adiponectin concentration is the consequence of adipo-
nectin binding to the LPS and the infecting bacteria.
4. Increased urine secretion – While there are conflicting
data as to whether chronic renal diseases are associated
with higher w127x or lower w122x circulating adiponectin
concentrations, than in normal subjects, several studies
have demonstrated an increase in urine adiponectin in the
presence of renal dysfunction w47, 94, 121x. Transient
renal insufficiency with a decrease in creatinine clearance
of at least 50% or more is reported in )25% of patients
with pyelonephritis w72, 116x. Thus, a possible explana-
tion for the lower maternal plasma adiponectin could be
increased secretion of this adipokine in the urine. Further
studies are needed in order to establish the relationship
between maternal serum and urine adiponectin in
pyelonephritis.
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In conclusion, acute pyelonephritis in pregnancy is char-
acterized by low maternal plasma concentrations of adipo-
nectin. The present study represents the first work to describe
an in vivo association between acute bacterial infection and
altered circulating adiponectin concentrations. The unique
combination of the biologic properties of adiponectin and its
important role in energy homeostasis and inflammatory pro-
cesses supports a role for this adipokine in the complex link-
age between metabolism and infection. As pregnancy is char-
acterized by physiologic adaptations involving metabolic
processes and immunologic systems, the regulation of these
two systems is particularly pertinent during normal gestation
and complications of pregnancy. Taken together, the findings
reported herein support a role for adiponectin in the intricate
interface between pregnancy, inflammation and metabolism.
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